Abstract
Predicting the trajectory of rare degenerative diseases can be extremely beneficial, especially when these predictions are personalised to be relevant for a specific patient. These predictions can help inform and advise patients, families, and clinicians about the next stages of treatment and care. Obtaining such predictions, however, can be challenging, especially when data is limited. In particular, it is important that these predictions do not rely too heavily on general trends from the wider afflicted population while not relying exclusively on the, potentially sparse, data from the patient in question. We present a case study, wherein a modelling framework is developed for predicting a patient’s long term trajectory, using a mix of data from the patient of concern and a database of previously observed patients. This framework directly accounts for the temporal structure of a patient’s trajectory, effortlessly handles a large amount of missing data, allows for a wide range of patient progression, and offers a robust quantification of the various uncertainties. We showcase this framework to an example involving Duchenne Muscular Dystrophy, where it provides promising results.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work received funding from the EPSRC via grant EP/T017856/1. Support was also provided by the National Institute for Health Research (NIHR) Biomedical Research centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London, as well as by Muscular Dystrophy UK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work used data obtained previously by the NorthStarUK network, and approval was given to perform this work. The North Star clinical network study was reviewed by the North Sheffield Research Ethics Committee and it was felt that it did not need to go to a research ethics committee. Written informed consent was obtained for the collection of all clinical data and the NorthStar clinical network project has Caldicott Guardian approval. All clinical assessments are conducted according to the principles of the Declaration of Helsinki (2000) and its later amendments and the Principles of Good Clinical Practice.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data may be available upon reasonable request to either Ian Bamsey (ian.bamsey@certus-tech.com; Managing Director at Certus Technology, which hosts the database), or Francesco Muntoni (f.muntoni{at}ucl.ac.uk)